Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 8, 2011, Pages 3922-3928

  Bertsche, Ute ^a   Weidenmaier, Christopher ^a   Kuehner, Daniel ^a   Yang, Soo Jin ^b,d   Baur, Stefanie ^a   Wanner, Stefanie ^a   Francois, Patrice ^c   Schrenzel, Jacques ^c   Yeaman, Michael R ^b,d   Bayer, Arnold S ^b,d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; MUROPEPTIDE; PEPTIDE DERIVATIVE; PEPTIDOGLYCAN; TEICHOIC ACID; UNCLASSIFIED DRUG;

ACETYLATION; ALANYLATION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CELL WALL; CHEMICAL REACTION; CORRELATION ANALYSIS; DRUG TREATMENT FAILURE; ENDOCARDITIS; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE; TRANSMISSION ELECTRON MICROSCOPY;

ALANINE; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CELL WALL; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; ENDOCARDITIS, BACTERIAL; HUMANS; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, TRANSMISSION; PEPTIDOGLYCAN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICHOIC ACIDS; URIDINE DIPHOSPHATE N-ACETYLMURAMIC ACID;

EID: 79960310756     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01226-10     Document Type: Article

References (40)

1. Bera, A., S. Herbert, A. Jakob, W. Vollmer, and F. Gotz. 2005. Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus. Mol. Microbiol. 55:778-787.
2. Boneca, I. G., Z. H. Huang, D. A. Gage, and A. Tomasz. 2000. Characterization of Staphylococcus aureus cell wall glycan strands, evidence for a new beta-N-acetylglucosaminidase activity. J. Biol. Chem. 275:9910-9918.
3. Boucher, H. W., and G. Sakoulas. 2007. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin. Infect. Dis. 45:601-608.
4. Burian, M., et al. 2010. Temporal expression of adhesion factors and activity of global regulators during establishment of Staphylococcus aureus nasal colonization. J. Infect. Dis. 201:1414-1421.
5. Camargo, I. L., H. M. Neoh, L. Cui, and K. Hiramatsu. 2008. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob. Agents Chemother. 52:4289-4299.
6. Cui, L., E. Tominaga, H. M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082.
7. de Jonge, B. L., Y. S. Chang, D. Gage, and A. Tomasz. 1992. Peptidoglycan composition of a highly methicillin-resistant Staphylococcus aureus strain. The role of penicillin binding protein 2A. J. Biol. Chem. 267:11248-11254.
8. D'Elia, M. A., et al. 2006. Lesions in teichoic acid biosynthesis in Staphylococcus aureus lead to a lethal gain of function in the otherwise dispensable pathway. J. Bacteriol. 188:4183-4189. (Pubitemid 43865737)
9. Fischer, A., et al. 28 May 2011, posting date. Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J. Antimicrob. Chemother. doi:10.1093/jac/dkr195.
10. Hayashi, K. 1975. A rapid determination of sodium dodecyl sulfate with methylene blue. Anal. Biochem. 67:503-506.
11. Hayden, M. K., et al. 2005. Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43:5285-5287.
12. Jones, T., et al. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 52:269-278.
13. Julian, K., et al. 2007. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51:3445-3448.
14. Kohlrausch, U., and J. V. Holtje. 1991. One-step purification procedure for UDP-N-acetylmuramyl-peptide murein precursors from Bacillus cereus. FEMS Microbiol. Lett. 62:253-257.
15. Kosowska-Shick, K., et al. 2006. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 27 to 30 September 2006, abstr. C1-685, p. 77.
16. Kraus, D., et al. 2007. Muropeptide modification-amidation of peptidoglycan D-glutamate does not affect the proinflammatory activity of Staphylococcus aureus. Infect. Immun. 75:2084-2087.
17. Kristian, S. A., et al. 2005. D-Alanylation of teichoic acids promotes group a streptococcus antimicrobial peptide resistance, neutrophil survival, and epithelial cell invasion. J. Bacteriol. 187:6719-6725. (Pubitemid 41356245)
18. Mishra, N. N., et al. 2009. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:2312-2318.
19. Muthaiyan, A., J. A. Silverman, R. K. Jayaswal, and B. J. Wilkinson. 2008. Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob. Agents Chemother. 52:980-990.
20. Peschel, A., et al. 1999. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274:8405-8410.
21. Sakoulas, G., et al. 2003. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J. Infect. Dis. 187:929-938.
22. Sakoulas, G., et al. 2008. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J. Clin. Microbiol. 46:220-224.
23. Schneider, T., et al. 2009. The lipopeptide antibiotic friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate. Antimicrob. Agents Chemother. 53:1610-1618.
24. Schneider, T., et al. 2004. In vitro assembly of a complete, pentaglycine interpeptide bridge containing cell wall precursor (lipid II-Gly5) of Staphylococcus aureus. Mol. Microbiol. 53:675-685.
25. Schriever, C. A., C. Fernandez, K. A. Rodvold, and L. H. Danziger. 2005. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am. J. Health Syst. Pharm. 62:1145-1158.
26. Silverman, J. A., N. G. Perlmutter, and H. M. Shapiro. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544.
27. Skiest, D. J. 2006. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J. Clin. Microbiol. 44:655-656.
28. Stranden, A. M., K. Ehlert, H. Labischinski, and B. Berger-Bachi. 1997. Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus. J. Bacteriol. 179:9-16. (Pubitemid 26428459)
29. Stranden, A. M., M. Roos, and B. Berger-Bachi. 1996. Glutamine synthetase and heteroresistance in methicillin-resistant Staphylococcus aureus. Microb. Drug Resist. 2:201-207.
30. Straus, S. K., and R. E. Hancock. 2006. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 1758:1215-1223.
31. Weidenmaier, C., et al. 2004. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat. Med. 10:243-245.
32. Weidenmaier, C., R. M. McLoughlin, and J. C. Lee. 2010. The zwitterionic cell wall teichoic acid of Staphylococcus aureus provokes skin abscesses in mice by a novel CD4+ T-cell-dependent mechanism. PLoS One 5:e13227.
33. Weidenmaier, C., and A. Peschel. 2008. Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions. Nat. Rev. Microbiol. 6:276-287.
34. Weidenmaier, C., et al. 2005. Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. J. Infect. Dis. 191:1771-1777.
35. Wootton, M., A. P. MacGowan, and T. R. Walsh. 2006. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob. Agents Chemother. 50:4195-4197.
36. Xia, G., and A. Peschel. 2008. Toward the pathway of S. aureus WTA biosynthesis. Chem. Biol. 15:95-96.
37. Yang, S. J., et al. 2009. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J. Infect. Dis. 200:1916-1920.
38. Yang, S. J., et al. 2010. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob. Agents Chemother. 54:3079-3085.
39. Yang, S. J., et al. 2005. A LysR-type regulator, CidR, is required for induction of the Staphylococcus aureus cidABC operon. J. Bacteriol. 187:5893-5900.
40. Yang, S. J., et al. 2009. Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrob. Agents Chemother. 53:2636-2637.